OXT and myeloid sarcoma: Recently, Amini-Khoei et al. (2017) demonstrated that intracerebral administration of OXT reduced pro-inflammatory gene expression related to microglia activity, including TNF-α, IL-1β, and TLR4, in the HIP of adult animals exposed to MS [128].